Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Albumin for Aneurysmal Subarachnoid Hemorrhage
NCT06548477Recruiting
- Sponsor
- Hamad Medical Corporation
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of human albumin in aneurysmal subarachnoid hemorrhage (SAH) (2 arms), sponsored by Hamad Medical Corporation. Primary endpoint: modified Rankin Scale at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
human albumin
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06548477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548477.